Bohemine

• CAT Number: M039761
• CAS Number: 189232-42-6
• Molecular Formula: C18H24N6O
• Molecular Weight: 340.431
• Purity: ≥95%
• Target: Cyclin-Dependent Kinases
• Solubility: Soluble in DMSO
• Storage: Store at -20°C
• IUPAC Name: 3-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]propan-1-ol
• InChI: InChI=1S/C18H24N6O/c1-13(2)24-12-21-15-16(20-11-14-7-4-3-5-8-14)22-18(23-17(15)24)19-9-6-10-25/h3-5,7-8,12-13,25H,6,9-11H2,1-2H3,(H2,19,20,22,23)
• InChIKey: OPQGFIAVPSXOBO-UHFFFAOYSA-N
• SMILES: CC(C)N1C=NC2=C1N=C(N=C2NCC3=CC=CC=C3)NCCCO

Bohemine is a potent and selective, cell-permeable, cyclin-dependent kinase (CDK) inhibitor with IC50 = 1 µM. Bohemine is structurally similar to Olomoucine and Roscovitine.

Reference

1:Conformation and recognition of DNA damaged by antitumor cis-dichlorido platinum(II) complex of CDK inhibitor bohemine. Novakova O, Liskova B, Vystrcilova J, Suchankova T, Vrana O, Starha P, Travnicek Z, Brabec V.Eur J Med Chem. 2014 May 6;78:54-64. doi: 10.1016/j.ejmech.2014.03.041. Epub 2014 Mar 15. PMID: 24675180 2:Cellular response to antitumor cis-Dichlorido platinum(II) complexes of CDK inhibitor Bohemine and its analogues. Liskova B, Zerzankova L, Novakova O, Kostrhunova H, Travnicek Z, Brabec V.Chem Res Toxicol. 2012 Feb 20;25(2):500-9. doi: 10.1021/tx200525n. Epub 2012 Feb 1. PMID: 22250642 3:Diverse effects of the cyclin-dependent kinase inhibitor bohemine: Concentration- and time-dependent suppression or stimulation of hybridoma culture. Franek F, Strnad M, Havlícek L, Siglerová V, Fismolová I, Eckschlager T.Cytotechnology. 2001 Jul;36(1-3):117-23. doi: 10.1023/A:1014020415912. PMID: 19003322 Free PMC Article4:In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, Garrett MD, Rogers P, Clarke SJ, Kelland LR, Valenti M, Brunton L, Eccles S, Lane DP, Workman P.Clin Cancer Res. 2005 Jul 1;11(13):4875-87. PMID: 16000586 Free Article5:Mixed ligand complexes of platinum(II) and palladium(II) with cytokinin-derived compounds Bohemine and Olomoucine: X-ray structure of [Pt(BohH+-N7)Cl(3)].9/5H2O [Boh=6-(benzylamino)-2-[(3-(hydroxypropyl)-amino]-9-isopropylpurine, Bohemine]. Trávnícek Z, Malon M, Zatloukal M, Dolezal K, Strnad M, Marek J.J Inorg Biochem. 2003 Apr 1;94(4):307-16. PMID: 12667701 6:Application of proteomics in the search for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases inhibitor, bohemine. Kovarova H, Halada P, Man P, Dzubak P, Hajduch M.Technol Cancer Res Treat. 2002 Aug;1(4):247-56. PMID: 12625783 7:In vitro biotransformation of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine by mouse liver microsomes. Rypka M, Veselý J, Chmela Z, Riegrová D, Cervenková K, Havlícek L, Lemr K, Hanus J, Cerný B, Lukes J, Michalíková K.Xenobiotica. 2002 Nov;32(11):1017-31. PMID: 12487731 8:Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine. Kovárová H, Hajdúch M, Korínková G, Halada P, Krupicková S, Gouldsworthy A, Zhelev N, Strnad M.Electrophoresis. 2000 Nov;21(17):3757-64. PMID: 11271495 9:In vivo metabolism of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine in mice: glucosidation as the principal metabolic route. Chmela Z, Veselý J, Lemr K, Rypka M, Hanus J, Havlícek L, Krystof V, Michnová L, Fuksová K, Lukes J.Drug Metab Dispos. 2001 Mar;29(3):326-34. PMID: 11181503 Free Article